Literature DB >> 931206

Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction.

J LeLorier, D Grenon, Y Latour, G Caillé, G Dumont, A Brosseau, A Solignac.   

Abstract

The kinetics of the elimination of lidocaine upon discontinuation of lidocaine infusions lasting more than 24 h were studied in 12 patients with uncomplicated myocardial infarctions. In this group of patients the mean half-life of the elimination phase was found to be 3.22 h. This is significantly different from the half-life of 100 min that has been reported after bolus injections or infusions lasting less than 12 h. This longer half-life should be taken into consideration in estimating the duration of toxicity and the rate of administration of the drug during and after intravenous infusions lasting 24 h or more.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 931206     DOI: 10.7326/0003-4819-87-6-700

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  34 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 2.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 3.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

4.  The appropriate dosage regime for the transition from intravenous lignocaine to oral tocainide after acute myocardial infarction.

Authors:  J W Upward; D Holt; P Emery; F Akhras; G Jackson
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

6.  Rapid prediction of individual dosage requirements for lignocaine.

Authors:  S Vozeh; M Berger; M Wenk; R Ritz; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

7.  The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects.

Authors:  A H Thomson; H L Elliott; A W Kelman; P A Meredith; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

8.  alpha 1-Acid glycoprotein and plasma lidocaine binding.

Authors:  D G Shand
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of lignocaine.

Authors:  N L Benowitz; W Meister
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

10.  Lignocaine and indocyanine green kinetics in patients following myocardial infarction.

Authors:  N D Bax; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.